Several highly specific ERβ agonists like ERB-041 and WAY200070 have been reported to trigger tumor suppressive responses in OC cells in vitro and could therefore be evaluated for efficacy in mouse models and clinical settings. The gene discussed is ESR2; the disease is neoplasm.